丁二酸洛沙平结构式
|
常用名 | 丁二酸洛沙平 | 英文名 | Loxapine succinate |
|---|---|---|---|---|
| CAS号 | 27833-64-3 | 分子量 | 445.896 | |
| 密度 | N/A | 沸点 | 458.6ºC at 760mmHg | |
| 分子式 | C22H24ClN3O5 | 熔点 | 150-152°C | |
| MSDS | 中文版 美版 | 闪点 | 231.1ºC |
丁二酸洛沙平用途Loxapine琥珀酸盐是D2/D4多巴胺受体,5羟-色胺受体抑制剂。 |
| 中文名 | 丁二酸洛沙平 |
|---|---|
| 英文名 | loxapine succinate |
| 中文别名 | 洛沙平琥珀酸酯 | 2-氯-11-(4-甲基哌嗪-1-基)二苯并[b,f][1,4]氧氮杂卓丁二酸盐 |
| 英文别名 | 更多 |
| 描述 | Loxapine琥珀酸盐是D2/D4多巴胺受体,5羟-色胺受体抑制剂。 |
|---|---|
| 相关类别 | |
| 参考文献 |
| 沸点 | 458.6ºC at 760mmHg |
|---|---|
| 熔点 | 150-152°C |
| 分子式 | C22H24ClN3O5 |
| 分子量 | 445.896 |
| 闪点 | 231.1ºC |
| 精确质量 | 445.140442 |
| PSA | 102.67000 |
| LogP | 3.01860 |
| 外观性状 | 白色固体 |
| 储存条件 | -20°C Freezer |
| 水溶解性 | H2O: soluble |
| 计算化学 | 1.疏水参数计算参考值(XlogP):无 2.氢键供体数量:2 3.氢键受体数量:7 4.可旋转化学键数量:4 5.互变异构体数量:无 6.拓扑分子极性表面积103 7.重原子数量:31 8.表面电荷:0 9.复杂度:542 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:2 |
| 更多 | 1. 性状:白色固体 2. 密度(g/mL,25/4℃):未确定 3. 相对蒸汽密度(g/mL,空气=1):未确定 4. 熔点(ºC):150-152 5. 沸点(ºC,常压):未确定 6. 沸点(ºC,5.2kPa):未确定 7. 折射率:未确定 8. 闪点(ºC):未确定 9. 比旋光度(º):未确定 10. 自燃点或引燃温度(ºC):未确定 11. 蒸气压(kpa,20ºC):未确定 12. 饱和蒸气压(kPa,60ºC):未确定 13. 燃烧热(KJ/mol):未确定 14. 临界温度(ºC):未确定 15. 临界压力(KPa):未确定 16. 油水(辛醇/水)分配系数的对数值:未确定 17. 爆炸上限(%,V/V):未确定 18. 爆炸下限(%,V/V):未确定 19. 溶解性:溶于水 |
| 个人防护装备 | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| 危害码 (欧洲) | Xi |
| 危险品运输编码 | UN 2811 6.1 / PGII |
| WGK德国 | 3 |
| RTECS号 | WM5750000 |
|
Investigation of the disposition of loxapine, amoxapine and their hydroxylated metabolites in different brain regions, CSF and plasma of rat by LC–MS/MS
J. Pharm. Biomed. Anal. 58 , 83-93, (2012) Loxapine represents an interesting example of old “new” drug and is recently drawing attention for its novel inhalation formulation for the treatment of both psychiatric and non-psychiatric disorders.... |
|
|
In vitro aerosol characterization of Staccato(®) Loxapine.
Int. J. Pharm. 403(1-2) , 101-8, (2011) Medicinal aerosol products (metered dose and dry powder inhalers) require characterization testing over a wide range of use and pre-operating stress scenarios in order to ensure robust product perform... |
|
|
Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
Int. J. Clin. Pract. 66(3) , 318-25, (2012) To describe the efficacy of inhaled loxapine for the treatment of agitation associated with schizophrenia or bipolar disorder using different examples of effect size (ES).Psychopharmacologic Drug Advi... |
| 2-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine succinate (1:1) |
| Succinic acid - 2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]oxazepine (1:1) |
| Daxolin |
| Butandisäure--2-chlor-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepin(1:1) |
| loxapine succinate salt |
| acide butanedioïque - 2-chloro-11-(4-méthylpipérazin-1-yl)dibenzo[b,f][1,4]oxazépine (1:1) |
| MFCD00069298 |
| Loxitane |
| Cloxazepin |
| Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-, butanedioate (1:1) |
| Loxapac |
| EINECS 248-682-0 |
| butanedioic acid,8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine |
| 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine butanedioate |
| Lederle |
| 2-Chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]oxazepine succinate |
| Loxapine succinate |
| Loxapine (succinate) |